* Says co’s Wuhan-based unit signs joint development agreement with Chengdu Easton Biopharmaceuticals Co., Ltd.
* Says Chengdu Easton Biopharmaceuticals will transfer CX3002 APIs and tablet related technologies in China market to unit
* Says transaction amount of 50 million yuan
Source text in Chinese: goo.gl/jVweno
Further company coverage: (Beijing Headline News)